Miklishanskaia S V, Liakishev A A, Kukharchuk V V
Kardiologiia. 2013;53(3):59-70.
Inflammation plays an important role in origin and progression of atheromatous plaque. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered a biomarker of inflammation and a predictor of vascular events. Lp-PLA2 is an enzyme secreted by leukocytes and associated with circulating lipoproteins and macrophages in atherosclerotic plaques. Lp-PLA2 hydrolizes phospholipids of oxidized low density lipoproteins and generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a major role in the development of atherosclerotic lesions, myocardial infarction and ischemic stroke. Recently the first publications appeared about selective inhibitor of phospholipase A2 - darapladib as a novel therapeutic approach for the treatment of patients with coronary artery disease. However, first results need to be confirmed by ongoing large long-term randomized clinical trials.
炎症在动脉粥样硬化斑块的发生和发展中起重要作用。脂蛋白相关磷脂酶A2（Lp-PLA2）被认为是一种炎症生物标志物和血管事件的预测指标。Lp-PLA2是一种由白细胞分泌的酶，与循环脂蛋白以及动脉粥样硬化斑块中的巨噬细胞相关。Lp-PLA2水解氧化型低密度脂蛋白的磷脂，并生成两种促炎介质，即溶血磷脂酰胆碱和氧化型非酯化脂肪酸，它们在动脉粥样硬化病变、心肌梗死和缺血性卒中的发展中起主要作用。最近，关于磷脂酶A2选择性抑制剂——达帕利单抗作为治疗冠心病患者的一种新治疗方法的首批文献问世。然而，初步结果需要正在进行的大型长期随机临床试验予以证实。
